2026-10-28 11:02:02 UTC#527971newforecastdata release
EYPT stock news
EYPT stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-20 18:43:00 UTC#488397newconfirmednews
Laidlaw & Co. downgrades EyePoint Pharmaceuticals (EYPT) to Hold from Buy
2026-10-20 13:18:45 UTC#486688newconfirmednews
RBC Capital maintains Sector Perform rating on EyePoint Pharmaceuticals, sets $1 price target
tradingviewimportance 0.40trust 0.60RBC Capital Markets -0.20EyePoint Pharmaceuticals, Inc. -0.50DURAVYU -0.50
2026-10-19 22:20:00 UTC#483510newconfirmednews
EyePoint Pharmaceuticals average analyst price target lowered to $20.89 from $22.33
2026-10-19 13:45:00 UTC#480902duplicateconfirmednews
EyePoint Pharmaceuticals shares fall 81% after second Phase 3 trial failure for Duravyu and 50% workforce cut
2026-10-19 12:38:10 UTC#480459duplicateconfirmednews
EyePoint Pharmaceuticals shares decline following failed Phase 3 trial for lead drug
2026-10-19 12:19:00 UTC#480329duplicateconfirmednews
EyePoint Pharmaceuticals shares drop 82% after Duravyu fails Phase 3 trial and company announces 50% workforce cut
2026-10-19 11:38:01 UTC#480075updateconfirmednews
EyePoint Pharmaceuticals to cut workforce by 50% following failed Phase 3 trial for DURAVYU
2026-10-19 11:13:00 UTC#479927newconfirmednews
EyePoint's DURAVYU misses primary endpoint in LUCIA Phase 3 trial for wet AMD, despite 38% reduction in injections
tradingviewimportance 0.70trust 0.80EyePoint Pharmaceuticals, Inc. -0.80DURAVYU -0.80aflibercept +0.20+2 entities
2026-09-21 11:28:15 UTC#341921newconfirmednews
EyePoint Pharmaceuticals reports DURAVYU/LUGANO wet AMD data, sets clinical timelines and grants stock options
tradingviewimportance 0.30trust 0.70EyePoint Pharmaceuticals, Inc. +0.20DURAVYU +0.20LUGANO +0.20+1 entities
2026-09-15 12:25:56 UTC#313619duplicateconfirmednews
EyePoint Pharmaceuticals (EYPT) maintains positive outlook on secondary trial data ahead of LUCIA study
2026-09-15 11:53:15 UTC#313407newreportedanalysis
EyePoint Pharmaceuticals (EYPT) outlook improves on strong secondary trial data ahead of pivotal LUCIA study
quartrimportance 0.40trust 0.50EyePoint Pharmaceuticals, Inc. +0.40LUCIA +0.30Diabetic Macular Edema +0.20
2026-09-10 15:30:29 UTC#293354updateconfirmednews
EyePoint Pharmaceuticals details LUGANO trial secondary outcomes, pivots to LUCIA for regulatory approval
2026-09-10 15:09:30 UTC#293230updateconfirmednews
EyePoint Pharmaceuticals to leverage LUGANO learnings for LUCIA Phase III, data expected in late Q4
2026-09-10 11:13:01 UTC#291391newconfirmednews
EyePoint reports LUGANO Phase 3 DURAVYU results, targets wet AMD NDA filing for H1 2027
2026-09-02 14:09:14 UTC#256473duplicateconfirmednews
EyePoint Pharmaceuticals shares fall following TD Cowen downgrade
2026-09-02 13:30:00 UTC#256173newconfirmednews
TD Cowen downgrades EyePoint Pharmaceuticals to Hold from Buy, slashes price target to $4 from $20
2026-09-02 11:49:25 UTC#255340newconfirmednews
Premarket movers: Dell jumps 8% on raised sales forecast; Credo falls 9%, FuelCell drops 15%
2026-08-28 23:10:00 UTC#237639newconfirmednews
Kessler Topaz Meltzer & Check, LLP launches investigation into EyePoint, Inc. following failed DURAVYU Phase 3 trial
pr_newswireimportance 0.40trust 0.50EyePoint Pharmaceuticals, Inc. -0.60Kessler Topaz Meltzer & Check, LLP -0.10DURAVYU -0.70
2026-08-18 16:00:00 UTC#190644newconfirmednews